Easy-to-Read Informed Consent Form for Hematopoietic Cell Transplantation Clinical Trials: Results from the Blood and Marrow Transplant Clinical Trials Network 1205 Study

被引:13
|
作者
Spellecy, Ryan [1 ]
Tarima, Sergey [1 ]
Denzen, Ellen [2 ,3 ]
Moore, Heather [2 ]
Abhyankar, Sunil [4 ]
Dawson, Peter [5 ]
Foley, Amy [2 ,3 ]
Gersten, Iris [5 ]
Horwitz, Mitchell [6 ]
Idossa, Lensa [2 ]
Joffe, Steven [7 ]
Kamani, Naynesh [8 ]
King, Roberta [2 ]
Lazaryan, Aleksandr [9 ]
Morris, Lawrence [10 ]
Horowitz, Mary M. [1 ,11 ]
Majhail, Navneet S. [12 ]
机构
[1] Med Coll Wisconsin, Ctr Bioeth & Med Humanities, Milwaukee, WI 53226 USA
[2] Natl Marrow Donor Program, Minneapolis, MN USA
[3] Ctr Int Blood & Marrow Transplant Res, Minneapolis, MN USA
[4] Kansas Univ, Med Ctr, Dept Hematol Malignancies & Cellular Therapies, Kansas City, KS USA
[5] EMMES Corp, Rockville, MD USA
[6] Duke Univ, Dept Hematol Malignancies & Cellular Therapy, Durham, NC USA
[7] Univ Penn, Div Med Eth, Philadelphia, PA 19104 USA
[8] AABB, Bethesda, MD USA
[9] Univ Minnesota, Dept Hematol Oncol & Transplantat, Minneapolis, MN USA
[10] Northside Hosp, Blood & Marrow Transplant Program, Atlanta, GA USA
[11] Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI USA
[12] Cleveland Clin, Blood & Marrow Transplant Program, Cleveland, OH 44195 USA
关键词
Clinical trials; Research subjects; Informed consent; Blood and Marrow Transplant; Clinical Trials Network: hematopoietic cell transplantation; CANCER; PARTICIPATION; DOCUMENTS; CHILDREN;
D O I
10.1016/j.bbmt.2018.04.014
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Because of the complexity of hematopoietic cell transplant trial treatments, informed consent forms are often long and difficult to read. We evaluated a 2-column easy-to-read informed consent (ETRIC) form that incorporates elements of health literacy and readability in participants and centers participating in Blood and Marrow Transplant Clinical Trials Network (BMT CTN) clinical trials. In a randomized study 198 adult patients from 25 centers potentially eligible to participate in 4 BMT CTN interventional trials were randomized to the ETRIC form or a standard consent form for that trial. Both forms were written at no more than an eighth-grade reading level. The primary endpoint was objective comprehension score on the Quality of Informed Consent, part A (QulC-A) instrument. In a parallel evaluation study, 2 moderators conducted semistructured interviews of 49 investigators, research staff, and institutional review board (IRB) members at 9 BMT CTN trial sites. The mean QulC-A scores were comparable in 152 patients (77%) assessable for the primary endpoint (ETRIC form, 80.5; standard form, 81.8; P = .37). In regression analysis there was no significant association between the consent type and QulC-A score. In the evaluation study dominant themes identified on qualitative analyses included general comfort and willingness to use the ETRIC template and that its formatting and layout enhancements would offer additional value to research participants, investigators, and IRBs. IRB language preferences and requirements, length, and prior experience with alternative consent formats were perceived as barriers. Among patients considering participation in BMT CTN clinical trials, the formatting enhancements of the ETRIC form did not alter comprehension of the trial. Despite local challenges to implementation, trial sites generally viewed the ETRIC form favorably and expressed willingness to use it over standard consent form. (C) 2018 American Society for Blood and Marrow Transplantation.
引用
收藏
页码:2145 / 2151
页数:7
相关论文
共 50 条
  • [31] Implementation of the Exception From Informed Consent Regulations in a Large Multicenter Emergency Clinical Trials Network: The RAMPART Experience
    Silbergleit, Robert
    Biros, Michelle H.
    Harney, Deneil
    Dickert, Neal
    Baren, Jill
    ACADEMIC EMERGENCY MEDICINE, 2012, 19 (04) : 448 - 454
  • [32] A Multicenter Phase II Trial of Unrelated Donor Reduced Intensity Bone Marrow Transplantation for Children with Severe Sickle Cell Disease (SCURT): Results of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0601) Study
    Shenoy, Shalini
    Eapen, Mary
    Wu, Juan
    Walters, Mark C.
    Levine, John E.
    Logan, Brent
    Gersten, Iris D.
    Kamani, Naynesh R.
    BLOOD, 2015, 126 (23)
  • [33] Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network
    Laport, Ginna G.
    Wu, Juan
    Logan, Brent
    Bachanova, Veronika
    Hosing, Chitra
    Fenske, Timothy
    Longo, Walter
    Devine, Steven M.
    Nademanee, Auayporn
    Gersten, Iris
    Horowitz, Mary
    Lazarus, Hillard M.
    Riches, Marcie L.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (08) : 1440 - 1448
  • [34] Follistatin and Endoglin: Potential Biomarkers of Endothelial Damage and Non-Relapse Mortality after Myeloablative Allogeneic Hematopoietic Cell Transplantation in Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0402
    Newell, Laura F.
    DeFor, Todd E.
    Cutler, Corey S.
    Verneris, Michael R.
    Blazar, Bruce R.
    Antin, Joseph H.
    Howard, Alan
    Wu, Juan
    MacMillan, Margaret L.
    Panoskaltsis-Mortari, Angela
    Weisdorf, Daniel J.
    Holtan, Shernan G.
    BLOOD, 2016, 128 (22)
  • [35] Follistatin and Endoglin: Potential Biomarkers of Endothelial Damage and Non-Relapse Mortality after Myeloablative Allogeneic Hematopoietic Cell Transplantation in Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0402
    Newell, Laura F.
    Defor, Todd E.
    Cutler, Corey S.
    Verneris, Michael R.
    Blazar, Bruce R.
    Antin, Joseph H.
    Howard, Alan
    Wu, Juan
    MacMillan, Margaret L.
    Panoskaltsis-Mortari, Angela
    Weisdorf, Daniel J.
    Holtan, Shernan
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (03) : S73 - S74
  • [36] Proceedings from the Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple Myeloma
    Holstein, Sarah A.
    Asimakopoulos, Fotis
    Azab, Abdel Kareem
    Bianchi, Giada
    Bhutani, Manisha
    Crews, Leslie A.
    Cupedo, Tom
    Giles, Hannah
    Gooding, Sarah
    Hillengass, Jens
    John, Lukas
    Kaiser, Shari
    Lee, Lydia
    Maclachlan, Kylee
    Pasquini, Marcelo C.
    Pichiorri, Flavia
    Shah, Nina
    Shokeen, Monica
    Shy, Brian R.
    Smith, Eric L.
    Verona, Raluca
    Usmani, Saad Z.
    McCarthy, Philip L.
    TRANSPLANTATION AND CELLULAR THERAPY, 2022, 28 (08): : 446 - 454
  • [37] Randomized clinical trials for hematopoietic stem cell transplantation: lessons to be learned from the European experience
    S S Kuthiala
    G H Lyman
    O F Ballester
    Bone Marrow Transplantation, 2006, 37 : 219 - 221
  • [38] Randomized clinical trials for hematopoietic stem cell transplantation: lessons to be learned from the European experience
    Kuthiala, SS
    Lyman, GH
    Ballester, OF
    BONE MARROW TRANSPLANTATION, 2006, 37 (02) : 219 - 221
  • [39] Do patients participating in oncology clinical trials understand the informed consent form? A Brown University Oncology Research Group study
    Schumacher, Andrew
    Bartley, Carolyn
    Kaplan, Anne
    Murphy, Benjamin
    Safran, Howard
    Rosati, Kayla
    Wilson, Donna
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (34)
  • [40] Functional and Radiologic Assessment of the Brain after Reduced-Intensity Unrelated Donor Transplantation for Severe Sickle Cell Disease: Blood and Marrow Transplant Clinical Trials Network Study 0601
    King, Allison A.
    McKinstry, Robert C.
    Wu, Juan
    Eapen, Mary
    Abel, Regina
    Varughese, Taniya
    Kamani, Naynesh
    Shenoy, Shalini
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (05) : E174 - E178